Press

Acarix publishes annual report for 2019

 

Malmö, April 23, 2020

Today, Thursday April 23, Acarix is publishing its Annual Report for 2019..

The Annual Report is also attached to this press release.

PR_Acarix Annual Report 2019

Acarix Year-end report 2019

PR_Acarix_Årsredovisning 2019

Acarix Årsredovisning 2019

 

 

About Acarix
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor system calculates a patient-specific CAD-score non-invasively in less than10 minutes and can help rule out more than one third of patients with at least 96% certainty of not being sick (in a population with approx. 10% CAD prevalence). Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, certifiedadviser@redeye.se) is Certified Advisor of Acarix.

For more information, please visit www.acarix.com.